Investigating the Next-Generation of Cancer Therapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (5 December 2018) | Viewed by 250
Special Issue Editors
Interests: non-viral; nucleofection; CAR-T; CRISPR; genome editing
Interests: immunotherapy; cancer immunotherapy; T cell engineering; gene editing
Interests: translational Science; biomarkers; clinical development; immuno-oncology; neurodegenerative disease
Interests: radiol
Special Issue Information
Dear Colleagues,
Immunotherapy is a term that embodies new hope in the fight against cancer and other diseases, by exploiting the body’s own immune system to fight disease, and was recognized by Science Magazine as the 2013 “Scientific Breakthrough of the Year”. After years of claiming that this year or that decade represented the “Golden Age of Biotechnology”, and though there have indeed been many notable discoveries and improvements on existing therapies and strategies, we are now on the cusp of implementing new and innovative cancer therapies that in many ways represent the first real return on the investments made in biotechnology over the past decades. From PD-1/PD-L1 antagonists or knockouts to the very latest in CAR-T therapies, there is justifiable optimism for the future of the treatment of cancer; there are myriad ways in which these new ideas can be exploited, some of which will be explored in the course of this issue.
However, regardless of the optimism over these innovative approaches to cancer therapy, it is also incumbent on us to look at the ramifications of large scale implementation of these therapies, and the desirability to make these therapies more affordable, available, and insurable for the general public.
Dr. Gregory F. Alberts
Dr. Richard Morgan
Dr. Terry Fisher
Dr. Ildiko Csiki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- CAR-T
- genome editing
- CRISPR
- cancer
- checkpoint inhibitors
- translational medicine
- neoantigen
- biomarkers
- personalized medicine
